US 12,240,832 B2
IRAK4 inhibitors
Ina Terstiege, Sodertalje (SE); and Stefan Schiesser, Sodertalje (SE)
Assigned to ASTRAZENECA AB, Sodertalje (SE)
Filed by ASTRAZENECA AB, Sodertalje (SE)
Filed on Mar. 21, 2024, as Appl. No. 18/612,156.
Application 18/612,156 is a continuation of application No. PCT/EP2023/053416, filed on Feb. 13, 2023.
Claims priority of provisional application 63/267,956, filed on Feb. 14, 2022.
Prior Publication US 2024/0300923 A1, Sep. 12, 2024
Int. Cl. C07D 401/14 (2006.01); A61K 31/4439 (2006.01); A61K 31/444 (2006.01); A61K 31/501 (2006.01); C07D 401/12 (2006.01); C07D 405/14 (2006.01); C07D 413/14 (2006.01)
CPC C07D 401/14 (2013.01) [A61K 31/4439 (2013.01); A61K 31/444 (2013.01); A61K 31/501 (2013.01); C07D 401/12 (2013.01); C07D 405/14 (2013.01); C07D 413/14 (2013.01)] 4 Claims
 
1. A compound which is N-(1-Cyclopropyl-2-oxo-1,2-dihydropyridin-3-yl)-2-((1 S,4r)-4-((S)-2-hydroxy-N-methylpropanamido)cyclohexyl)-6-methoxy-2H-indazole-5-carboxamide:

OG Complex Work Unit Chemistry
or a pharmaceutically acceptable salt thereof.